Comparative therapeutic results of penicillin plus chloramphenicol versus ampicillin plus sulbactam in childhood meningococcemia. 1993

G Kanra, and G Seçmeer, and H Ozen, and M Ceyhan, and Z Ecevit
Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Fifty-seven cases of meningococcemia were evaluated retrospectively. The age of the patients ranged between 2 and 17 years. Of the 57 patients investigated for the efficacy of antibiotic treatment, 31 (54.4%) were treated with benzylpenicillin plus chloramphenicol and 26 (45.6%) with ampicillin plus sulbactam. Patients with criteria for a poor prognosis (presence of disseminated intravascular coagulation, low arterial blood pressure, and altered consciousness) were divided equally into two treatment groups. There were no statistically significant differences between the two treatment groups except for the higher incidence of convulsion in the group given penicillin plus chloramphenicol. The mortality rate was 19.3 percent for patients treated with benzylpenicillin plus chloramphenicol and 7.6 percent for patients treated with ampicillin plus sulbactam (p = 0.19; overall mortality rate 14%).

UI MeSH Term Description Entries
D008297 Male Males
D008589 Meningococcal Infections Infections with bacteria of the species NEISSERIA MENINGITIDIS. Meningococcal Septicemia,Infections, Meningococcal,Meningococcal Disease,Infection, Meningococcal,Meningococcal Diseases,Meningococcal Infection,Septicemia, Meningococcal
D010406 Penicillins A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002701 Chloramphenicol An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) Cloranfenicol,Kloramfenikol,Levomycetin,Amphenicol,Amphenicols,Chlornitromycin,Chlorocid,Chloromycetin,Detreomycin,Ophthochlor,Syntomycin
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G Kanra, and G Seçmeer, and H Ozen, and M Ceyhan, and Z Ecevit
July 1986, The Journal of pediatrics,
G Kanra, and G Seçmeer, and H Ozen, and M Ceyhan, and Z Ecevit
September 1985, Lancet (London, England),
G Kanra, and G Seçmeer, and H Ozen, and M Ceyhan, and Z Ecevit
September 1985, Lancet (London, England),
G Kanra, and G Seçmeer, and H Ozen, and M Ceyhan, and Z Ecevit
January 1988, Scandinavian journal of infectious diseases,
G Kanra, and G Seçmeer, and H Ozen, and M Ceyhan, and Z Ecevit
January 1986, Reviews of infectious diseases,
G Kanra, and G Seçmeer, and H Ozen, and M Ceyhan, and Z Ecevit
January 1986, Reviews of infectious diseases,
G Kanra, and G Seçmeer, and H Ozen, and M Ceyhan, and Z Ecevit
January 1988, Drugs,
G Kanra, and G Seçmeer, and H Ozen, and M Ceyhan, and Z Ecevit
January 1986, Reviews of infectious diseases,
G Kanra, and G Seçmeer, and H Ozen, and M Ceyhan, and Z Ecevit
January 1991, International journal of clinical pharmacology research,
Copied contents to your clipboard!